GILOTRIF®

Drug Information Related Patent

Hold Company

BOEHRINGER INGELHEIM

Dosage and Administration

TABLET;ORAL

Specification

EQ 20MG BASE; EQ 30MG BASE; EQ 40MG BASE

Indication

GILOTRIF® is indicated for EGFR mutation-positive, metastatic non-small cell lung cancer as well as metastatic squamous NSCLC.

Use

Instructions for Use

API

AFATINIB DIMALEATE

API Structure

We Supply

Note:

Facility GMP
USMF/ASMF

Note:

null

Note:

null

Drug Patent

API Patent

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Member of